Introduction
============

Although less than one percent of the global under-5 y of age population are HIV-infected,[@R1] these children account for 10.8% of the approximately 870 000 annual deaths attributed to *Streptococcus pneumoniae*, including 19.8% of pneumococcal deaths in African children.[@R2] In the absence of antiretroviral treatment (ART), *S. pneumoniae* is the leading bacterial opportunistic infection with the risk of invasive pneumococcal disease (IPD) being 40-fold greater in HIV-infected children.[@R3]^-^[@R5] In settings such as Southern Africa where the prevalence of HIV in children is less than 5% more than 65% of all IPD cases occur in HIV-infected children.[@R3]^,^[@R5] Although the susceptibility to IPD is reduced by 41% in HIV-infected children when treated with ART, the risk nevertheless remains 21-fold (95% CI: 16 to 28) greater compared with HIV-uninfected children.[@R3]

Similarly HIV-infected adults have 10--300 times greater susceptibility to IPD compared with HIV-uninfected individuals[@R6]^-^[@R10] and are at greater risk of recurrent IPD, with up to 25% of individuals having an additional episode within the next 12 mo.[@R11]^,^[@R12] In HIV-infected adults the initiation of ART has been associated with marked reductions in morbidity and mortality from opportunistic infections, including two- to 3-fold reductions in the risk of IPD.[@R7]^,^[@R10] Nevertheless, in the USA the incidence of IPD in HIV-infected adults in the era of ART continued to be approximately 35-fold greater than the general population.[@R10]

The increased susceptibility of HIV-infected individuals to pneumococcal disease in part relates to impairment of both cell-mediated and humoral arms of the immune system. An immunologic response to pneumococcal polysaccharides, a T-cell independent type antigen, elicits production of serotype-specific opsonic antibodies by B lymphocytes independent of T-lymphocyte interaction.[@R13] Both T- and B- lymphocytes are decreased and function impaired in HIV-infected individuals.[@R14]^,^[@R15] This results in impaired quantitative and qualitative antibody responses to natural infections and vaccination.[@R16]^,^[@R17] ART partially reconstitutes the immune system of HIV-infected individuals, by increasing B- and T- lymphocyte number and functionality. However, deficiencies in humoral response because of depleted or persistent defects in memory cell function persist after ART initiation.[@R18]

Vaccines available to protect against pneumococcal disease include a 23-valent pneumococcal polysaccharide vaccines (PPV) and polysaccharide-protein conjugate vaccines (PCV). PPV is licensed for use in adults and children older than 2 y; and particularly recommended for elderly persons and others with specified underlying medical conditions.[@R19] In adults PPV reduces the risk of IPD and in some studies decreased the risk of pneumonia.[@R20]^-^[@R22] However drawbacks of PPV vaccination include that vaccine-induced antibody concentrations declined within 1--2 y post-vaccination.[@R23]^,^[@R24] In addition, PPV being processed as a T-cell independent antigen does not prime for anamnestic responses, is dominated by an IgM antibody response and may result in hypo-responsiveness following subsequent doses of vaccine.[@R25]^-^[@R27] PPV vaccination in children has also not consistently being associated with a reduction in risk of nasopharyngeal colonization with vaccine-serotype pneumococci.[@R28] In young children, PPV is associated with poor immunogenicity, especially for serotypes causing the majority of childhood pneumococcal disease, due to immaturity of the T-cell independent immune system in these children.[@R29]

PCV induces a T-cell dependent immune response, which matures while in utero*,* and has an improved immunogenicity profile including in groups of individuals at high risk of IPD.[@R30]^-^[@R32] Currently there are three licensed PCV formulation for use in children and adolescents, including 7-valent \[PCV7, Prev(e)nar™; Pfizer Inc.\], 10-valent (PCV10, Synflorix™; GlaxoSmithKline) and 13-valent (Prevenar13™, Pfizer Inc.)

Previous reviews on PCV in adults has had limited emphasis to HIV-infected individuals.[@R33]^,^[@R34] In addition the last review of PCV in HIV-infected children was reported in 2008,[@R35] since when there have been a number of new studies in HIV-infected children. This review provides and updated analysis on the safety, efficacy and immunogenicity of PCV in HIV-infected individuals.

Methods
=======

Data for this review were identified by doing a literature search on PubMed using combinations of the following search terms: "pneumococcus," "pneumococcal," "*Streptococcus pneumoniae*," "pneumococcal conjugate vaccine," "HIV," "conjugate vaccine," "immunogenicity," "efficacy" and "safety." Only English language studies were reviewed, no date restrictions were set and no attempt at statistical analysis was undertaken.

Results
=======

Measures of immunogenicity of PCV in children and adults
--------------------------------------------------------

The benchmark for measuring the immunogenicity of new formulations of PCV is based on recommendations of a WHO working group.[@R36] This includes the proportion of subjects who attain serotype-specific antibody concentration of ≥0.35 μg/ml measured by enzyme-linked immunosorbent assay (ELISA) following a primary series of PCV for serotypes included in PCV7. This threshold of antibody is a putative measure of protection against IPD at a community-level in otherwise healthy children but does not necessarily indicate protection at an individual level nor is it serotype-specific.[@R36]^,^[@R37] The same threshold of antibody, albeit not validated, has been used as a measure of immunogenicity in HIV-infected children in more recent studies.[@R16]^,^[@R38]^,^[@R39] Immunogenicity studies in adults and older children have primarily reported on the proportion of children with a pre-defined increase in serotype-specific antibody concentration, as the majority of older individuals will have had serotype-specific antibody concentrations of ≥0.35 μg/ml through naturally acquired antibody stimulation mainly from nasopharyngeal colonization before vaccination.

The immunogenicity of PCV is also corroborated by the geometric mean antibody concentrations (GMCs) and the functionality of induced antibody measured by an opsonophagocytic activity assay (OPA). The latter includes measuring the geometric mean antibody titers (GMTs) and proportion of subjects with measurable OPA activity (i.e., OPA ≥ 8). Studies indicate that there may be a closer association using a serotype-specific threshold of OPA ≥ 8 than antibody concentration ≥0.35 μg/ml as a measure of protection against IPD at least for some serotypes such as 6B and 19F.[@R16]^,^[@R40] Similarly, OPA measurements may be more important in predicting potential efficacy for additional serotypes included in newer formulation of PCV than antibody concentration thresholds, as suggested by animal model studies of PCV13 for serotype 3.[@R41] It is also important, particularly in the context of HIV in children and other high-risk groups in whom the risk of IPD may persist beyond that in the general population, that the anamnestic responses induced by PCV be included in the evaluation of the immunogenicity of the vaccines.

### Immune responses to PCV vaccination in HIV-infected compared with -uninfected children

Three different PCV formulations, all containing CRM-197 (cross-reactive material) as the carrier protein, including PCV7 and experimental 5-valent PCV (PCV5) and experimental 9-valent PCV (PCV9), have been evaluated for immunogenicity in HIV-infected children.[@R16]^,^[@R38]^,^[@R39]^,^[@R42]^-^[@R49] In addition, studies on the safety and immunogenicity of PCV10 (which has protein-D, tetanus toxoid and diphtheria toxoid as carrier proteins) and PCV13 (also containing CRM-197) are currently underway with results expected in 2012/3. Direct comparisons between the immunogenicity studies among HIV-infected children are difficult since they varied in the dosing schedules used, vaccination age, immunological endpoints analyzed, clinical stage of HIV/AIDS disease and immunosuppression levels of the participants and the proportion of participants on ART ([Table 1](#T1){ref-type="table"}).

###### **Table 1.** PCV immunogenicity studies in HIV-infected children

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country and Reference   Study vaccines                                  Vaccine schedule^\#^                                                         Time of sampling                            Participants                               \% on ART at first vaccine dose   Presented endpoints
  ----------------------- ----------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------ --------------------------------- -------------------------------------------------------------------------------------------
  US[@R44]                PPV^a^\                                         Arm 1: PPV (D0)\                                                             D0, D42, D84                                2--9 y\                                    not mentioned in manuscript       ELISA GMC; fold-rise in GMC; % of responders (4 fold-rise)
                          PCV5^b^                                         Arm 2: PCV (D0)+ PPV (D42)                                                                                               n = 30 HIV-infected\                                                         
                                                                                                                                                                                                   n = 30 HIV-uninfected                                                        

  US[@R45]                PCV5^b^\                                        Arm 1: PCV (D0)+ PCV (D60)+ PCV (D120)\                                      D0, D60, D120, D150                         ≤ 2 y\                                     not mentioned in manuscript       ELISA GMC; fold-rise in GMC; % of responders (GMC ≥ 1 μg/ml)
                          Placebo (16 HIV-uninfected participants only)   Arm 2: placebo at same timepoints                                                                                        n = 18 HIV-infected\                                                         
                                                                                                                                                                                                   n = 33 HIV-uninfected                                                        

  US[@R43]\               PCV5^b^\                                        Arm 1: PCV (D0)+ PCV (D60)+ PCV (D120)\                                      D0, D150, D360                              ≤ 2 y\                                     not mentioned in manuscript       ELISA GMC; Percent drop in GMC; % of responders (GMC ≥ 1 μg/ml)
  Follow-up study         Placebo (11 HIV-uninfected participants only)   Arm 2: placebo at same timepoints                                                                                        n = 16 HIV-infected\                                                         
                                                                                                                                                                                                   n = 25 HIV-uninfected                                                        

  US[@R47]                PCV7^c^\                                        Arm 1: PCV (D0)+ PCV (D56)+ PCV (D112)+ PCV (15 mo of age)\                  D0, D240, pre-booster, post-booster, D730   56--180 d\                                 71% (11% on protease inhibitor)   ELISA GMC; fold-rise in GMC; % of responders (4-fold-rise)
                          Placebo                                         Arm 2: placebo at same timepoints\                                                                                       n = 45 HIV-infected                                                          
                                                                          (arms randomized 2:1)                                                                                                                                                                                 

  South Africa[@R16]      PCV9^d^\                                        Arm 1: PCV (6 weeks of age)+ PCV (10 weeks of age)+ PCV (14 weeks of age)\   1 mo after 3 dose                           n = 66 HIV-infected\                       No                                ELISA GMC; % of responders (GMC ≥ 0.35 μg/ml);\
                          Placebo                                         Arm 2: placebo at same timepoints                                                                                        n = 127 HIV-uninfected                                                       OPA

  Greece[@R48]            PCV7^e^                                         HIV-infected: PCV (D0)+ PCV (D30)+ PCV (D365)\                               D0, D30, D60, D365, D395                    128 mo (mean age)\                         79%                               ELISA GMC; fold-rise in GMC; % of responders (2 fold-rise for 4 serotypes);\
                                                                          HIV-uninfected: PCV (D0)+ PCV (D365)                                                                                     n = 14 HIV-infected\                                                         Avidity
                                                                                                                                                                                                   n = 21 HIV-uninfected                                                        

  Spain[@R49]             PCV7^e^                                         PCV (D0)+ PCV (D60)                                                          D0, D60, D150                               11 y (mean age)\                           100%                              ELISA GMC for ST: 6B, 14, 23F; OPA titers;\
                                                                                                                                                                                                   n = 56 HIV-infected                                                          % of responders (2 fold-rise in GMC and OPA titers; from negative to positive OPA levels)

  US[@R42]                PPV^a^\                                         PCV (D0)+ PCV (56)+ PPV (D112)                                               D0, D56, D112, D168, D336, D672             2--19 y\                                   100%                              ELISA GMC for ST: 1, 6B, 14, 19F, 23F; % of responders (GMC ≥ 0.5 μg/mL or ≥ 1 μg/mL)
                          PCV7^e^                                                                                                                                                                  n = 225 HIV-infected                                                         

  South Africa[@R38]\     Group 1: PCV9^d^\                               Arm 1: PCV (6 weeks of age)+ PCV (10 weeks of age)+ PCV (14 weeks of age)\   5 y after dose 3                            n = 31 HIV-infected vaccinees\             No                                \% of responders for PCV7 ST (GMC ≥ 0.2 μg/ml or ≥ 0.35 μg/ml)
  Follow-up study         Group 2: Placebo                                Arm 2: placebo at same timepoints                                                                                        n = 49 HIV-infected placebo\                                                 
                                                                                                                                                                                                   n = 98 HIV-uninfected vaccines\                                              
                                                                                                                                                                                                   n = 116 HIV-uninfected placebo                                               

  South Africa[@R46]      PCV7^e^                                         PCV (5 y post-primary series)                                                Pre- and post- vaccination                  n = 31 HIV-infected previous vaccinees\    20%                               ELISA GMC; % of responders (GMC ≥ 0.35 μg/mL); OPA for ST: 6B, 9V and 19F
                                                                                                                                                                                                   n = 45 HIV-infected previous placebo\                                        
                                                                                                                                                                                                   n = 89 HIV-uninfected previous vaccines\                                     
                                                                                                                                                                                                   n = 110 HIV-uninfected previous placebo                                      

  South Africa[@R39]      PCV7^e^                                         PCV (6--12 weeks)+ PCV (9--18 weeks)+ PCV (12--24 weeks)                     1 mo after 3 dose                           n = 249 HIV-infected\                      69%                               ELISA GMC; % of responders (GMC ≥ 0.35 μg/mL); OPA for ST: 9V, 19F and 23F
                                                                                                                                                                                                   n = 234 HIV-uninfected                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes: ^\#^, When not specified the different vaccination arms enrolled subjects 1:1; ELISA GMCs, geometric mean antibody concentrations measured by enzyme-linked immunosorbent assay; % of responders: percentage of subjects who achieved a predefine endpoint; ST, serotype; OPA, opsonophagocytic activity assay. ^a^Pnu-Immune 23 (25 μg of each capsular polysaccharide). ^b^10 μg of capsular polysaccharide from serotypes: 6B, 14, 18C, 19F, and 23F, covalently conjugated to CRM197. ^c^2 μg of capsular polysaccharide from serotypes 1, 4, 5, 9V, 14, 19F and 23F; 4μg of capsular polysaccharide from serotype 6B and 2 μg of oligosaccharide from serotype 18C covalently conjugated to CRM197. ^d^2 μg of capsular polysaccharide from serotypes 4, 9V, 14, 18C, 19F and 23F and 4 μg of capsular polysaccharide from serotype 6B covalently conjugated to CRM197. ^e^Prevnar, Wyeth-Lederle (2 μg of capsular polysaccharide from serotypes 4, 9V, 14, 18C, 19F and 23F and 4 μg of capsular polysaccharide from serotype 6B covalently conjugated to CRM197)

Comparison of immune responses to PCV vaccination between HIV-infected and -uninfected children were reported in seven studies.[@R16]^,^[@R38]^,^[@R39]^,^[@R43]^-^[@R45]^,^[@R48] Quantitative comparisons were made comparing the proportion of vaccinees who achieved either a pre-defined serotype-specific antibody concentration[@R16]^,^[@R38]^,^[@R39]^,^[@R43]^,^[@R45] or a pre-determined fold-rise in antibody concentration from baseline to post-vaccination.[@R44]^,^[@R48] In addition, qualitative responses using OPA and long-term anamnestic effects have been evaluated in the South African studies ([Table 1](#T1){ref-type="table"}).[@R16]^,^[@R39]

PCV vaccination, together with the other routine infant childhood vaccines, has been evaluated in two studies from South Africa and one from US.[@R16]^,^[@R39]^,^[@R47] In the South African studies, PCV was scheduled to be given at 6, 10 and 14 weeks of age with immunogenicity measured one month after the three-dose primary series of vaccine; [Table 1](#T1){ref-type="table"}.[@R16]^,^[@R39] The study by Nachman et al. evaluated a three-dose schedule during infancy spaced two months apart and a booster dose at 15 mo of age.[@R47] In the absence of ART in African children, one month after a primary three-dose series of PCV9 (which included PCV7 serotypes and serotypes 1 and 5), the proportion of HIV-infected vaccinees with antibody concentrations ≥0.35 μg/ml to vaccine serotypes ranged between 63 to 93% compared with 79 to 100% in HIV-uninfected infants. This proportion was lower in HIV-infected compared with --uninfected children for serotypes 1 (p = 0.03), 5 (p = 0.03), 18C (p = 0.03) and 23F (p = 0.04) ([Fig. 1](#F1){ref-type="fig"}). Similarly GMCs were lower in HIV-infected children for all serotypes, albeit only significantly so for serotypes 1 and 18C.[@R16] The differences in response to PCV were, however, even more pronounced on OPA for all three analyzed serotypes (6B, 19F and 23F). The proportion of HIV-infected infants with OPA ≥8 was lower in HIV-infected compared with --uninfected infants for serotypes 6B (78% vs. 96%), 19F (46% vs. 91%) and 23F (57% vs. 93%) ([Fig. 2](#F2){ref-type="fig"}). The proportion of HIV-infected subjects with OPA titers ≥8 was more closely associated than the proportion with antibody concentration of ≥0.35 μg/ml, in relation to 65% efficacy against vaccine-serotype IPD observed in HIV-infected children from the same population.[@R50] In addition, HIV-infected children had lower GMTs and required higher concentration of antibody for 50% killing activity on OPA. The higher antibody concentration required for comparable OPA killing activity in HIV-infected compared with --uninfected children suggest functional impairment of antibody in HIV-infected children. Thus, the threshold of antibody concentration required for preventing IPD in HIV-infected children may be higher than the ≥0.35 μg/ml putative threshold suggested for the general population of children.

![**Figure 1.** Proportion of responders with GMCs ≥ 0.35 μg/ml for the 7 serotypes included in PCV7. Data was derived from.[@R16]^,^[@R39] HIV+/PCV9/no ART: HIV-infected children vaccinated with three PCV9 doses not on ART. HIV+/PCV7/delay ART: HIV-infected children vaccinated with three PCV7 doses initiated on ART when clinically or immunologic indicated. HIV+/PCV7/ART: HIV-infected children vaccinated with three PCV7 doses on ART at the time of vaccination. HIV-/PCV9: HIV-uninfected children vaccinated with three PCV9 doses. HIV-/PCV7: HIV-uninfected children vaccinated with three PCV7 doses.](hv-8-161-g1){#F1}

![**Figure 2.** Proportion of responders with OPA titers ≥ 8 for serotypes 6B, 9V, 19F and 23F. Data was derived from[@R16] for serotypes 6B, 19F and 23F and from[@R39] for serotypes 9V, 19F and 23F. HIV+/PCV9/no ART: HIV-infected children vaccinated with three PCV9 doses not on ART. HIV+/PCV7/delay ART: HIV-infected children vaccinated with three PCV7 doses initiated on ART when clinically or immunologic indicated. HIV+/PCV7/ART: HIV-infected children vaccinated with three PCV7 doses on ART at the time of vaccination. HIV-/PCV9: HIV-uninfected children vaccinated with three PCV9 doses. HIV-/PCV7: HIV-uninfected children vaccinated with three PCV7 doses.](hv-8-161-g2){#F2}

A follow-on study in the same setting, involved infants with access to ART.[@R39] This included a group of HIV-infected infants who were initiated on ART immediately upon being diagnosed as having HIV infection at 4--12 weeks of age and another group with CD4+ cell percentage ≥25% at the time of receipt of the primary series of PCV, but who were only initiated on ART when clinically or immunologic indicated as per previous WHO treatment guidelines.[@R51] The immunogenicity of PCV, measured by the proportion of vaccinees with antibody concentration of ≥0.35 μg/ml, was similar between HIV-uninfected and both groups of HIV-infected infants ([Fig. 1](#F1){ref-type="fig"}). These data corroborated the findings from an earlier study by Nachman et al. in which there was no difference in the GMCs in HIV-infected children, 71% of who were on protein-inhibitor based ART regimen, compared with a historical control group of HIV-uninfected infants.[@R47]

The study by Nachman et al. has not reported on OPA responses in those children. However, a significantly lower proportion of HIV-infected African infants in whom ART was delayed developed OPA titers of ≥8 to the three analyzed serotypes, despite CD4+ cell percentage ≥25% at vaccination, compared with HIV-uninfected infants or HIV-infected children who were initiated on immediate ART ([Fig. 2](#F2){ref-type="fig"}). The poorer qualitative immune response in the children in whom ART was deferred was also associated with lower OPA GMTs and higher concentration of antibody being required for 50% killing on OPA than in HIV-uninfected children.[@R39] The response in HIV-infected infants with CD4+ cell percentage ≥25% when vaccinated but in whom ART was deferred was, however, better relative to infants without any access to ART ([Fig. 1](#F1){ref-type="fig"} **and** [Fig. 2](#F2){ref-type="fig"}).[@R16] This comparison may, however, be biased as only children with a CD4+ cell percentage ≥25% at time of vaccination were included in the group in whom ART was deferred whereas the CD4+ cell counts in the group without access to ART was not evaluated. In addition, 17% of the children in whom ART was deferred had been initiated on ART by the time of measuring the immune response to the primary series of PCV.[@R39] These infant studies indicate that PCV immunization is associated with comparable immunogenicity as in HIV-uninfected infants when undertaken if CD4+ cell percentage is ≥25% and children have been initiated on early ART.

Other studies of PCV in HIV-infected children have mainly involved those older than one year of age and have evaluated different PCV schedules with or without PPV used as a booster/supplementary dose. In two small studies evaluating an investigational PCV5, which included much higher serotype polysaccharide concentration (10 μg per serotype) than in currently licensed formulations (2--4 μg per serotype), the percentage of protocol-defined responders, as per [Table 1](#T1){ref-type="table"}, although higher in HIV-uninfected children was not significantly different from the HIV-infected group at one month post-primary series.[@R45]^,^[@R48] However, the persistence of antibody was lower in HIV-infected compared with---uninfected children one year after the initial two-doses primary series of PCV.[@R45]^,^[@R48] The studies by King et al. differed to that of Spoulou et al. in that the former reported rapid and similar drop in antibody titers in HIV-infected and---uninfected children, although antibody concentrations were higher than at pre-vaccination.[@R43] In contrast, antibody levels were sustained in HIV-uninfected children 12 mo after the primary series in the study by Spoulou et al. compared with one month post-primary series concentration, whereas HIV-infected children experienced a decay in antibody concentrations to pre-vaccination concentrations.[@R48] Differences in vaccine formulation and study design could explain the observed differences in these studies. Differences included that Spoulou et al. recruited older children (mean age: 128 mo) most of them on ART (79%),[@R48] whereas the study by King et al. vaccinated younger children (mean age: 12.9 mo).[@R43] The observation that a second dose of PCV failed to induce any further increase in GMCs for all serotypes among older HIV-infected children may suggest the absence of PCV inducing anamnestic responses in these children.[@R48] Lower antibody concentrations and greater magnitude of decline in antibody concentration was also observed in ART-naïve HIV-infected children compared with HIV-uninfected children when measured five-years after the primary PCV series during infancy.[@R38]^,^[@R46]

### PCV booster effect in HIV-infected children

Immunologic memory in HIV-infected children previously primed with 2--3 doses of PCV was assessed by administrating a booster dose of PCV at approximately 12 mo after primary series[@R47]^,^[@R48] or at 5 y post-primary series.[@R46] When a booster dose of PCV was given at 15 mo of age after three primary doses during infancy which included 71% of participants on ART and symptomatic and asymptomatic children, anamnestic responses were detected.[@R47] This included higher serotype-specific antibody concentrations post-booster compared with pre-booster concentration; and the mean fold-change in antibody concentration being significantly higher compared with the group who had previously received placebo. Nevertheless PCV vaccinees experienced a significant waning of serotype-specific GMCs at 24 mo of age, although they remained above pre-immunization levels.[@R47] A booster dose of PCV in older symptomatic HIV-infected children (median age 128 mo), 79% of whom were on ART, however, induced only a modest increase in GMCs, indicating either absence of having induced or failure to sustain an anamnestic response.[@R48]

When HIV-infected children who received PCV9 (previous vaccinees) or placebo (control group) during infancy were vaccinated with one dose of PCV7 five years after the primary three dose series during infancy in South Africa, an increase in GMCs was observed for 6 of the 7 serotypes (all PCV7 serotypes except 19F) compared with pre-booster GMCs in HIV-infected children.[@R46] However, the magnitude in fold-change in concentrations was greater for only three serotypes (serotypes 4, 6B and 14) among HIV-infected previous vaccinees compared with previous placebo recipients. In addition, the proportion of children with antibody concentrations ≥0.35 μg/ml was higher for only two serotypes (serotypes 6B and 14) in previous PCV9-vaccinees compared with controls when measured one month after receipt of PCV.[@R46] Furthermore, irrespective of previous priming with PCV during infancy, post-booster GMCs and functional antibody activity were higher in HIV-uninfected than---infected children. These observations also demonstrated impairment in anamnestic immune responses in HIV-infected children. The study was not, however, able to determine whether the HIV-infected children had failed to develop immunologic memory after primary immunization or whether there was a subsequent loss of anamnestic responses with the HIV/AIDS disease progression.[@R46]

### Association of HIV/AIDS disease stage and PCV immune response in children

Most of the studies stratified HIV-infected children accordingly to clinical stage of AIDS or level of immunosuppression based on CD4+ cell measures. HIV-infected children in the absence of ART with CDC clinical category-C AIDS had lower GMCs to five (serotypes 5, 9V, 14, 18C and 23F) of the nine PCV9 serotypes, compared with children who were CDC clinical category N/A following completion of the primary series of PCV9.[@R16] A multicenter study in the US with HIV-infected children receiving ART, studied children aged 2--19 y who received two doses of PCV7 followed by one PPV dose eight weeks apart. This study demonstrated that higher antibody concentration at baseline, higher CD4+ cell percentage at vaccination, higher nadir CD4+ percentage, lower HIV-viral loads, longer duration of current ART regimen and younger age were predictors of better immune response in HIV-infected children.[@R42] In particular, children vaccinated early in the course of their HIV illness, including when the CD4+ cell percentage was ≥25% at its nadir and at the time of vaccination, had the greatest antibody increase in relation to prior antibody concentration after each dose of vaccine. In addition, antibody concentrations remained high in this group of children two years later. Conversely, immunization of children when both the nadir and time of vaccination CD4+ cell percentage was \<15%, showed poor antibody responses to both doses of PCV and the PPV. This study also identified a significant positive association between antibody concentration and the duration of the ART regimen.[@R42] These results support the importance of ART in lymphocyte reconstitution and the subsequent effect thereof on immunogenicity of PCV.

Other trials were less able to identify differences in response rates to PCV based on CD4+ cell count, immune status before ART or clinical AIDS stage.[@R43]^-^[@R45]^,^[@R47]^,^[@R49] In two of these studies a substantial proportion of children were, however, also taking ART.[@R47]^,^[@R49]

Efficacy of PCV in HIV-infected children
----------------------------------------

The efficacy of PCV has only been evaluated in HIV-infected children in a randomized placebo-controlled trial in South Africa. This study evaluated an investigational PCV9, which included serotypes 1 and 5 and was otherwise identical to PCV7.[@R50] The nine serotypes included in PCV9 covered 83--91% of invasive disease causing serotypes among HIV-infected children prior to the study.[@R9]^,^[@R35] PCV was found to be efficacious in preventing vaccine serotype-specific IPD in HIV-infected infants, who were not on ART. The vaccine efficacy, following 2.3 y of follow-up, against IPD in HIV-infected was 65% (95% CI: 24 to 86) and lower than observed in HIV-uninfected children (83%; 95% CI: 39 to 97).[@R50] However, because of the 40-fold greater burden of IPD pre-existent in HIV-infected children,[@R4] despite the lower vaccine efficacy, there was an 18-fold greater reduction in the burden of vaccine-serotype IPD prevented in HIV infected compared with --uninfected children (570 vs. 32 per 100 000 children vaccinated, respectively).[@R50]

PCV vaccination was also associated with non-significant reductions in overall mortality (6%; p \> 0.05) and reduction in radiologic confirmed pneumonia (13%; 95% CI: -7 to 29).[@R50] The lack of efficacy against the endpoint of radiologic confirmed pneumonia may, however, have been confounded in that this non-specific endpoint used as a surrogate for "pneumococcal pneumonia" may have had even less specificity in HIV-infected compared with -uninfected children.[@R52] This was corroborated in part by subsequent, post hoc analysis, in which using different criteria to define pneumonia revealed a 15% (95% CI: 5 to 24) reduction in all-cause clinical pneumonia and 59% (95% CI: 1 to 83) reduction in vaccine-serotype bacteremic pneumonia in HIV-infected children.[@R53] Furthermore, the low sensitivity of blood cultures in the diagnosis of pneumococcal pneumonia, even in HIV-infected children, was evident in that the vaccine-attributable rate reduction was 5.3-fold greater for all-cause clinical pneumonia (2 573 cases per 100 000 child-years prevented) compared with bacteremic pneumococcal pneumonia (483 per 100 000 child-years episodes).[@R53] Similarly to that observed for IPD, there was 9-fold greater reduction of all-cause clinical pneumonia in HIV--infected children compared with --uninfected children after 2.3 y of follow-up.[@R50]^,^[@R53] The South African study, through using PCV vaccination as a probe, also identified the important role of pneumococcal co-infection as a precipitating cause of hospitalization for respiratory viral and *Mycobacterium tuberculosis* associated pneumonia in HIV-infected children.[@R54]^,^[@R55]

At 5 y of follow-up in the South African study, in the absence of a booster dose of PCV or ART access, vaccine efficacy against IPD in HIV-infected children dropped from the initial 65% estimate at 2.3 y of age to 39% (95% CI: -8 to 65). In HIV-uninfected children, efficacy of a three-dose primary series of PCV against IPD remained unchanged at 5 y post-vaccination (78%; 95% CI: 34 to 93) compared with at 2.3 y (83%).[@R38] Despite this, the vaccine-attributable rate reduction in IPD, irrespective of serotype, in HIV-infected children (2 250 per 100 000 child-years prevented) was 59-fold greater compared with HIV-uninfected children (38 per 100 000 child-years prevented) by five years of age. The efficacy of PCV9 against any serotype IPD was, however, greater in HIV-infected children (46%) than in HIV-uninfected children (35%), mainly due to the cross-protection afforded by the PCV9 against serotype 6A.[@R38] All these data emphasize the need for sustained protection against IPD in HIV-infected children well beyond the first two years of life, which is when most disease occurs in HIV-uninfected children. Consequently, determination of anamnestic responses and persistence thereof are important measures when evaluating the immunogenicity of PCV in HIV-infected and possibly other high risk groups of children.

Safety of PCV in HIV-infected children
--------------------------------------

Five studies from the US or South Africa explored the safety of PCV in HIV-infected children.[@R42]^,^[@R44]^,^[@R45]^,^[@R47]^,^[@R50] In all the studies PCV was well tolerated and in the studies including a placebo arm, no significant differences in local or systemic reactions between placebo and PCV recipients were observed.[@R45]^,^[@R47] Nachman et al. however reported more frequent severe signs and symptoms among PCV recipients than placebo, and these included diarrhea, rash, fever and anemia.[@R47] In the South African study a higher rate of asthma was reported among PCV9 recipients, however no stratification by HIV-status was done for asthma rate. In addition, the 5-y follow-up period of this study revealed a lower CD4+ cell percentage, as well as a similar trend in mean CD4+ counts, in previous PCV recipients compared with past placebo recipients.[@R38] The clinical significance of the lower CD4+ cell count, in the absence of receiving ART, among previous PCV recipients in HIV-infected children remains to be explored.

Pneumoccocal polysaccharide vaccination in HIV-infected adults
--------------------------------------------------------------

Immunization with a single dose of PPV is recommended for HIV-infected adults and adolescents as soon as possible after diagnosis of HIV infection and who have a CD4+ cell count ≥ 200 cells/μl.[@R56]^-^[@R58] PPV vaccination of older HIV-infected children and adults has been associated with poor or modest immunogenicity.[@R44]^,^[@R59]^,^[@R60] Even in HIV-infected adults on ART, PPV elicited only modest increases in functional antibody and in serotype-specific antibody concentrations, with antibody responses being lower than in healthy controls.[@R61]^-^[@R63] The use of PPV in African HIV-infected adults is controversial. A randomized placebo-controlled trial in Uganda reported an increase in pneumonia in the six-month period following PPV vaccination of HIV-infected adults not on ART,[@R60] albeit subsequently suggesting a 16% reduction in all-cause mortality.[@R64] A recent meta-analysis by Pedersen et al., indicated marked heterogeneity in results on the efficacy of PPV against varying pneumococcal disease syndromes in HIV-infected adults and did not demonstrate any overall benefit.[@R65] The effectiveness of PPV in HIV-infected adults, and discrepant efficacy results between studies, may be associated with HIV viral load and correspondingly ART status at the time of vaccination.[@R60]^,^[@R61]^,^[@R64]^,^[@R66]^,^[@R67] Teshale et al. suggested that PPV related protection against pneumonia was only evident in individuals with HIV viral load of \< 100 000 copies/μl irrespective of CD4+ immunologic categorization.[@R68] Several studies have also shown that HIV-infected persons with CD4+ cell counts \< 500 cells/μl have impaired antibody responses against several pneumococcal serotypes compared with less immunocompromized HIV-infected persons or healthy controls.[@R59]^,^[@R69]

In less immunocompromized HIV-infected individuals, the rate of antibody decline after PPV vaccination is comparable to healthy controls. However, since HIV-infected individuals have lower post-vaccination antibody concentrations, their antibody concentrations may diminish to below the estimated protective levels sooner than in HIV-uninfected adults.[@R23]^,^[@R70] As there are no immunologic correlates of clinical protection against IPD for adults, immunogenicity studies in adults have used the same threshold (≥0.35 μg/ml) suggested for infants or higher thresholds such as 1 μg/ml, or the fold-increase in antibody concentration as immunologic endpoints when measuring the immunogenicity of PCV. In addition, some studies have also evaluated OPA responses.

Immunogenicity of PCV in HIV-infected adults
--------------------------------------------

[Table 2](#T2){ref-type="table"} summarizes the studies in which the immunogenicity and safety of PCV has been evaluated in HIV-infected adults, aimed at showing better potential than that conferred by PPV. To our knowledge only one published study reported on clinical efficacy of PCV vaccination in HIV-infected adults.[@R80] Several other studies have, however, explored the serotype-specific immune responses induced by PCV in adults with HIV.[@R69]^-^[@R79] Direct comparisons between studies were confounded in that some used PCV alone while other studies evaluated PCV in combination with PPV. Studies also varied in the definition of measuring immune responses, including the use of endpoints such as antibody concentration expressed as GMCs, functional antibody levels determined by OPA or avidity experiments and percentage of responders (fold-rise in post-vaccination antibody titers compared with pre-vaccination) ([Table 2](#T2){ref-type="table"}). Two of the studies[@R69]^,^[@R70] presented in [Table 2](#T2){ref-type="table"} measured serum antibody titers by ELISA without the currently recommended step of absorption with heterologous pneumococcal polysaccharides 22F to improve serotype-specific antibody specificity by inhibiting non-serotype specific antibodies.[@R81]

###### **Table 2.** PCV immunogenicity studies in HIV-infected adults

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study year, country and reference        Study vaccines   Vaccine schedule^\#^                                                   Time of sampling               Participants                \% on ART at first vaccine dose   CD4+ cell count at baseline (cells/μL)          Previous pneumococcal vaccination    Presented endpoints
  ---------------------------------------- ---------------- ---------------------------------------------------------------------- ------------------------------ --------------------------- --------------------------------- ----------------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------
  US (July--Dec 1993)^\$\ 69^              PPV23^a^\        Arm 1: PPV (D0)\                                                       D0, D30                        18--65 y\                   47%                               \< 200: 90 (group I)\                           No PPV in past 5 y                   ELISA GMC; fold-rise in GMC; % of responders (2-fold rise)
                                           PCV5^b^          Arm 2: PCV (D0)                                                                                       n = 183 HIV-infected\                                         ≥ 200: 93 (group II)                                                                 
                                                                                                                                                                  n = 99 HIV-uninfected                                                                                                                              

  The Netherlands^\$\ 70^                  PPV23^c^\        PCV (D0)+ PCV (D30)+ PPV (D300)\                                       D0, D30, D60, D300, D330\      16--62 y\                   100% of group I                   \< 200: 16 (group I); 26 historical controls\   Not mentioned in manuscript          ELISA GMC; fold-rise in GMC; % of responders (GMC ≥ 1 μg/ml)
                                           PCV4^d^          Historical controls: PPV (D0)                                          Historical controls: D0, D30   n = 30 HIV-infected\                                          ≥ 200: 14 (group II); 24 historical controls                                         
                                                                                                                                                                  n = 9 HIV-uninfected\                                                                                                                              
                                                                                                                                                                  Historical controls:\                                                                                                                              
                                                                                                                                                                  n = 50 HIV-infected\                                                                                                                               
                                                                                                                                                                  n = 10 HIV-uninfected                                                                                                                              

  US (Jan 1998--June 1999)[@R71]           PPV23^e^\        Arm 1: PCV (D0)+ PCV (D56)\                                            D0, D56, D112                  \> 17 y\                    42%                               ≥ 200                                           No PPV in past 5 y                   ELISA GMC for ST: 4, 6B, 6V, 14 and 23F; OPA titers for ST: 4, 6B, 6V, 14 and 23F; % of responders (2-fold in GMC or 4 fold-rise in OPA)
                                           PCV7^f^          Arm 2: PCV (D0)+ PPV (D56)\                                                                           n = 67 HIV-infected                                                                                                                                
                                                            Arm 3: Placebo (D0)+ PCV (D56)\                                                                                                                                                                                                                          
                                                            Arm4: Placebo (D0)+ PPV (D56)                                                                                                                                                                                                                            

  Uganda (Oct 2001--June 2002)[@R72]       PCV7^f^          PCV (D0)+ PCV (D28)\                                                   D0, D28, D56                   24--79 y\                   No                                \< 200: 43 (group I)\                           Previous PPV or placebo recipients   ELISA GMC; fold-rise in GMC; % of responders (2 fold-rise or GMC \> 0.35 μg/ml or GMC \> 1 μg/ml)
                                                            (median time from previously PPV/placebo administration (1:1) 62 mo)                                  n = 109 HIV-infected                                          200--499: 42 (group II)\                                                             
                                                                                                                                                                                                                                ≥ 500: 23 (group III)                                                                

  France (Dec 2002--Dec 2003)[@R73]        PPV23^g^\        Arm 1: PCV (D0)+ PPV (D28)\                                            D0, D28, D56, D168             44 y (mean age)\            87%                               200--500                                        No PPV in past 5 y                   ELISA GMC; % of responders (2 fold-rise and GMC ≥ 1 μg/mL)
                                           PCV7^f^          Arm 2: PPV (D28)                                                                                      n = 208 HIV-infected                                                                                                                               

  Malawi[@R74]                             PCV7             Arm 1: PCV7 (D0)\                                                      D0, D30, D180                  32 y (mean age)\            No                                \> 200                                          Not mentioned in manuscript          ELISA GMC in serum and Bronchoalveolar lavage for ST: 6B, 14, 19F and 23F
                                                            Arm 2: Placebo (D0)                                                                                   n = 19 HIV-infected\                                                                                                                               
                                                                                                                                                                  n = 22 HIV-uninfected                                                                                                                              

  Uganda (Jan--June 2005)[@R75]            PPV23^h^\        PCV (D0)+ PPV (D60)                                                    D0, D60, D90, D240             37 y (mean age)\            No                                200--499: 30 (group I)\                         Not mentioned in manuscript          ELISA GMC and OPA titers for ST: 4 and 14
                                           PCV7^f^                                                                                                                n = 58 HIV-infected\                                          ≥ 500: 28 (group II)                                                                 
                                                                                                                                                                  n = 29 HIV-uninfected                                                                                                                              

  Spain (Dec 2007--Apr 2008)[@R76]         PPV23\           Arm 1: PCV (D0)+ PPV (D28)\                                            D0, D28, D56                   44 y (mean age)\            98% PCV group\                    200--500                                        No previous PPV                      ELISA GMC;\
                                           PCV7             Arm 2: PPV (D28)                                                                                      n = 202 HIV-infected        91% PPV group                                                                                                          % of responders (2 fold-rise and GMC ≥ 1 μg/ml); Avidity

  US (Feb 2006--Sep 2008)[@R77]            PPV23^h^\        Arm 1: PCV (D0)\                                                       D0, D14, D60, D180             18--60 y old\               82%                               \< 200: 7 (group I)\                            PPV vaccinated 3--8 y earlier        ELISA GMC for ST: 4, 9V, 14 and 19F;\
                                           PCV7^f^          Arm 2: PPV (D0)\                                                                                      n = 131 HIV-infected PCV\                                     200--499: 84 (group II)\                                                             fold-rise in GMC;\
                                                            (arms randomized 2:1)                                                                                 n = 73 HIV-infected PPV\                                      ≥ 500: 113 (group III)                                                               % of responders (2 fold-rise for at least 2 serotypes and GMC ≥ 1 μg/ml)
                                                                                                                                                                  n = 25 HIV-uninfected                                                                                                                              

  Denmark (Jan--Mar 2008)[@R78]^,^[@R79]   PPV^i^\          PCV (D0)+ PCV (D90)+ PPV (D270)\                                       D0, D90, D120, D270, D300      ≥ 18 y old\                 79%                               ≥ 200                                           No PPV in past 5 y                   ELISA GMC;\
                                           PCV7^f^          (± CPG 7909\* to each vaccine dose)                                                                   n = 97 HIV-infected                                                                                                                                % of responders (2 fold-rise for at least 5 serotypes and GMC ≥ 1μg/ml);\
                                                                                                                                                                                                                                                                                                                     OPA titers (ST 6B, 14, 19F and 23F)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes: ^\#^, When not specified the different vaccination arms enrolled subjects 1:1; \*, Toll-like receptor agonist and vaccine adjuvant; ELISA GMCs, geometric mean antibody concentrations measured by enzyme-linked immunosorbent assay; % of responders, percentage of subjects who achieved a predefine endpoint; ST, serotype; OPA, opsonophagocytic activity assay. ^\$^ELISA performed not including absorption with heterologous 22F serotype. ^a^Pnu-Immune 23, Lederle, Wayne, NJ (25 μg of each capsular polysaccharide). ^b^Lederle-Praxis Biologics, Rochester, NY (10 μg of capsular polysaccharide from serotypes: 6B, 14, 18C, 19F, and 23F, covalently conjugated to CRM197). ^c^Pneumovax 23, Pasteur Merieux MSD, Amstelveen, The Netherlands (25 μg of each capsular polysaccharide). ^d^Merck and Co. Inc. West Point, PA (2 μg of capsular polysaccharide from serotypes 6B and 14 in one syringe and 2 μg of serotypes 19F and 23F in another, covalently conjugated to an outer membrane complex from Neisseria meningitis). ^e^Wyeth-Lederle (25 μg of each capsular polysaccharide). ^f^Prevenar Wyeth-Lederle (2 μg of capsular polysaccharide from serotypes 4, 9V, 14, 18C, 19F and 23F and 4 μg of capsular polysaccharide from serotypes 6B covalently conjugated to CRM197). ^g^Pneumo 23, Aventis Pasteur MSD. ^h^Pneumovax, Merck-Banyu (25 μg of each capsular polysaccharide). ^i^Pneumo Novum; sanofi-pasteur MSD.

Studies that included a PCV-vaccinated HIV-uninfected group as a control consistently detected a better antibody response in HIV-uninfected than in HIV-infected individuals.[@R69]^,^[@R70]^,^[@R74]^,^[@R75]^,^[@R77] An exception was the study by Chen, et al. where no difference in GMCs for serotype 4 between the HIV-infected and --uninfected groups was detected at any timepoint, although only two serotypes (4 and 14) were evaluated.[@R75]

### PCV immunogenicity vs. PPV in HIV-infected adults

A 4-arm randomized trial with two doses of vaccines and/or placebo administered to HIV-infected subjects 8 weeks apart (PCV7-PCV7, PCV7-PPV23, placebo-PPV23 and placebo-placebo groups) reported that antibody concentration and OPA 16 weeks after the initial vaccine dose were significantly higher in the groups that received PCV compared with the group that just received PPV for four of the five serotypes tested.[@R71] In addition, there was a trend for higher proportion of responders in the PCV-vaccinated group compared with the placebo-PPV group with regard to obtaining more than 2 fold-rise in GMCs or 4 fold-rise in OPA titers, albeit only significant for serotype 4. A second PCV dose eight weeks after the first PCV7 dose did not produced any further increase in antibody response.[@R71]

Another study with a shorter dosing schedule (4 weeks between vaccinations) but a longer follow-up period also found that the response profile was better in the arm that received a PCV dose followed by PPV 4 weeks later compared with the PPV-only group.[@R73] These differences were, however, only evident after the PCV group had received their PPV dose. Superiority of the PCV-PPV arm considering both antibody levels and percentage of responders was sustained at least until 24 weeks post-first dose.[@R73]

PCV vaccination of HIV-infected adults previously vaccinated with PPV 3--8 y earlier transiently induced a better immune response than PPV revaccination at 60 d post-vaccination.[@R77] However, at 180 d post-vaccination there was no difference in antibody concentration between the two groups, indicating that PCV vaccination provided little additional immunologic benefit compared with PPV re-vaccination.[@R77] While PCV elicited good antibody responses and in several studies higher than that induced by PPV at particular timepoints these differences were not markedly different. A study in Spain where PPV was given alone or 4 weeks after PCV did not find any difference between the two vaccination arms in serotype-specific antibody avidity and proportion of responders (defined as a 2 fold-rise in antibody titers and antibody concentration of at least 1 μg/ml), except for serotype 23F, in the PCV-group at 8 weeks post-PCV.[@R76]

### PCV priming of the immune system in HIV-infected adults

Vaccination with PCV followed by PPV allowed several studies to explore the possibility of priming of the immune system by PCV. Even though the interval between vaccines appears to play a role, evidences of inducing anamnestic responses are sparse.[@R70]^,^[@R71]^,^[@R73]^,^[@R75]^,^[@R76]^,^[@R78] In a study in Denmark where HIV-infected adults were immunized twice 3 mo apart with double the standard dose of PCV7 and received PPV nine months after the first-PCV7 dose, GMCs did not increase at one month post-PPV compared with one month post-second PCV dose levels. However, OPA titers were higher at one month post-PPV for three (i.e., 14, 19F and 23F) of the four serotypes assessed.[@R78] Since this study did not include a PPV-only arm, it is not clear if the increase in OPA titers post-PPV were due to anamnestic responses induced through priming with PCV.[@R78] Lesprit et al., however, reported that PPV given four weeks after PCV resulted in better immune response measured four weeks later, compared with HIV-infected adults only vaccinated with PPV. This included higher percentage of responders (defined as a 2-fold rise in GMCs from baseline and GMC ≥ 1ug/mL) and higher GMCs for six (i.e., 4, 9V, 14, 18C, 19F and 23F) of the serotypes common to PCV7 and PPV at four weeks post-PPV. The higher antibody concentration in PCV7 recipients was maintained at least until 20 weeks post-PPV for four serotypes, although the percentages of responders dropped in each group.[@R73] As evident by the results of these studies the dosing schedule and timing of vaccination of HIV-infected adults with pneumococcal vaccines still needs further investigation however a schedule with a dose of PCV followed by PPV seems the most adequate in possibly enabling induction of anamnestic immune responses by PCV as well as by expanding serotype coverage of those serotypes included in the 23-valent PPV but absent in PCV.

### Factors associated with PCV response in HIV-infected adults

Pneumococcal vaccines induced antibody responses are probably dependent on CD4+ cell function. Most of the studies that included HIV-infected persons with CD4+ cell counts less than 200 cells/μl, observed a lower antibody response to PCV compared with persons with counts higher than 200 cells/μl analyzing either absolute antibody concentrations[@R70]^,^[@R72] or fold-rise in antibody levels.[@R70] However it has been suggested that the association between CD4+ cell count and antibody response is mainly due to a direct association between CD4+ cell count and baseline antibody concentration.[@R72] When searching for factors associated with PCV-specific immunologic response CD4+ cell count, virologic status or receipt of ART at initiation of vaccine series were not significantly associated with differences in antibody concentration and OPA titers during follow-up until 60--112 d.[@R71]^,^[@R77] However, in one study after administration of two doses of double-strength PCV7 three months apart, HIV-infected adults on ART achieved a more durable antibody response, of higher magnitude than ART-naive individuals, independent of pre-vaccination CD4+ cell count.[@R78] Both ART-experienced and ART-naïve subjects achieved comparable initial responses to PCV, but after a period of 9 mo post-first PCV dose significant differences were apparent in the proportion of vaccine responders (defined as a 2-fold rise in GMCs from baseline to ≥ 1ug/mL for at least 5 serotypes) in the two ART groups.[@R78]

In search for a more immunogenic pneumococcal vaccine for use in HIV-infected adults the addition of an adjuvant was explored by Sogaard et al.[@R79] This study evaluated the inclusion of a toll-like receptor agonist and vaccine adjuvant (CPG7909) to PCV7 and PPV. In this study the proportion of vaccine high responders (defined as a 2-fold increase in antibody levels to \> 1 μg/mL for at least 5 serotypes) was higher in the CPG7909 group than among controls at 4, 9 and 10 mo. OPA titers were also elevated in the CPG7909 group. The enhanced production of antibodies by CPG7909 was, however, negatively correlated with HIV viral load indicating that this strategy was unlikely to benefit HIV-infected individuals with detectable HIV-viremia. Even though vaccination with the addition of CPG7909 was generally well tolerated, mild systemic and injection site reactions to first and/or second PCV dose were more common in the CGP7909 group than in the control group. After PPV immunization influenza-like symptoms were more common in the CPG7909 group.

Studies that report on HIV viral loads after vaccination, have not observed significant increases above pre-vaccination levels after one or two PCV doses.[@R71]^,^[@R77]

Clinical efficacy of PCV in HIV-infected adults
-----------------------------------------------

Although immunogenicity studies provide evidence of relative response between PCV and PPV, the absence of serologic correlates of protection against disease in HIV-infected individuals and in adults, requires demonstration of the efficacy of PCV against pneumococcal disease in HIV-infected adults. To date, there are no head-to-head randomized trials which compared the efficacy of PCV to that of PPV in HIV-infected adults. There have, however, been two separate double-blind, randomized, placebo-controlled clinical trials, one comparing PPV efficacy with placebo against pneumonia as discussed earlier and the other comparing PCV7 efficacy with placebo for protecting against recurrent vaccine-serotype IPD.[@R60]^,^[@R80]

The efficacy of PCV7 was assessed in Malawi from 2003 to 2007 in HIV-infected adolescents and adults (15 y of age or older) who had recovered from an IPD episode.[@R80] The primary end point was a further episode of IPD caused by PCV7 serotypes or serotype 6A. Two doses of PCV7 or placebo were given 4 weeks apart and subjects were followed up for a mean of 1.2 y. Overall 496 subjects were enrolled, 88% being HIV-infected and of those 13% were on ART at baseline. Twenty-four (36%) of all new IPD episodes (n = 67) were PCV7 or 6A serotype and the unadjusted vaccine efficacy was 74% (95% CI: 30 to 90) with a hazard ratio of 0.26 (95% CI: 0.10 to 0.70). Vaccine efficacy, however, decreased from 85% in the first year post-vaccination to 25% thereafter. Protection against IPD was also evident in the subgroup of participants with CD4+ cell counts \< 200 cells/μl, with a vaccine efficacy of 86% (95% CI: 41 to 97).[@R80] The overall protection against IPD, irrespective of serotype, had a hazard ratio of 0.72 (95% CI: 0.42 to 1.25). In addition, no overall effect was observed in mortality between PCV7 recipients (29%) and placebo recipients \[25%; adjusted hazard ratio: 1.24 (95% CI: 0.9 to 1.8)\]. CD4+ cell count at enrolment was the strongest risk factor for IPD in this study in a multivariable analysis. Compared with subjects with CD4+ cell counts higher than 500 cells/μl, patients with CD4+ cell counts \< 200 cells/μl had 7-times higher risk of a recurrent IPD episode. A lower CD4+ cell count was also associated with death and pneumonia from any cause.[@R80] The study was not powered to investigate the interaction between PCV and the use of ART. The greater diversity of serotypes causing IPD in adults may, however, require formulations of PCV with broadened serotype coverage than that included in the current formulation of PCV targeted primarily at serotypes highly prevalent in children.

Safety of PCV in HIV-infected adults
------------------------------------

The safety and tolerability of PCV administration in HIV-infected adults was comparable to PPV vaccination, both vaccines being generally well tolerated. Individuals who received PCV tended to reported more local pain at injection site than PPV recipients in two studies.[@R69]^,^[@R71] The frequency of other reactions including fever, redness, swelling and tenderness were similar in the two vaccine arms. The majority of reaction reported were self-limited. In the PCV efficacy trial in Malawi, serious adverse events were significantly more common in the placebo arm.[@R80] In the revaccination study by Crum-Cianflone et al., one HIV-infected PCV-vaccinated subject developed encephalitis 41 d after revaccination which was attributed as possibly being related to the vaccine.[@R77]

PCV and indirect protection
---------------------------

In addition to the direct effect of PCV, vaccination of young children has also been associated with reduction of vaccine-serotype IPD in the general population of unvaccinated individuals.[@R82]^,^[@R83] This reduction is attributed to the effectiveness of PCV in reducing the risk of nasopharyngeal acquisition of the targeted vaccine serotypes in vaccinated children, who are traditionally considered the most important source of transmission of pneumococci within communities.[@R84] In addition to indirect effect observed in the general US population,[@R85] widespread childhood PCV7 immunization has also been temporally associated with reduction in vaccine-serotype IPD in HIV-infected adults in US (91%).[@R86] The decline in overall IPD has, however, been offset by an increase in non-vaccine serotype IPD (28%) in this population with a net overall reduction of IPD being 41%.[@R86]^,^[@R87] In the analysis by Cohen et al. from 2004--2007, the incidence of IPD (cases per 100 000) in HIV-infected adults remained 40-times higher than among HIV-uninfected adults.[@R86] Although these data indicate the potential of childhood PCV immunization benefiting HIV-infected individuals from developing IPD, these findings need further exploration in African settings where there may be a greater diversity of serotypes associated with IPD compared with in the US. In addition, lower levels of childhood immunization coverage, differing dosing schedules and more limited catch-up campaigns of immunizing older children and possible differences in the dynamics of pneumococcal transmission in developing countries may affect the indirect potential of vaccines in some settings with a high prevalence of HIV-infection.

Conclusions
===========

Studies on PCV demonstrate promise for directly and indirectly protecting HIV-infected individuals against developing IPD and pneumonia. PCV vaccination of HIV-infected children on ART, particularly when immunologic competent when immunized, indicate similar quantitative and qualitative antibody responses as in HIV-uninfected children. However, the immunogenicity, efficacy and durability of protection of HIV-infected children not receiving ART indicates the need for possible booster doses of PCV later in life, albeit preferably after they been initiated on antiretroviral treatment. The frequency and timing of these additional booster doses in HIV-infected children independently of ART usage still needs to be determined to improve vaccine effectiveness. Furthermore long-term anamnestic responses to PCV are yet to be established in HIV-infected children vaccinated while receiving ART.

The introduction of PCV into national children immunization programs in settings with high HIV burden should be careful designed and should include catch-up campaigns targeting HIV-infected children not vaccinated during infancy to optimize the prevention of pneumococcal disease.

Although some studies in adults are inconsistent on the immunologic advantage of PCV over PPV, PCV has nevertheless been associated with protection against vaccine serotype IPD in high risk HIV-infected adults even largely in the absence of ART. However the limited serotype coverage of PCV (seven to 13 serotypes) requires HIV-infected individuals to also receive PPV in addition to PCV, to expand the coverage of potential disease causing serotypes.

The greatest benefit of PCV immunization programs against IPD may, however, be realized through the indirect effect of childhood vaccination against adult disease. This needs to be further explored, including for some of the newer serotypes included in PCV13 (e.g., 1, 3, 5 and 7F) and not PCV7 which may differ in the dynamics of transmission within communities. The indirect effect of PCV in protecting adults in settings with a high prevalence of HIV, particularly in Africa, needs further study since significant differences exist between these settings and developed countries regarding immunization practices and vaccine coverage. The magnitude of the herd effect was not confirmed on a small study in South Africa, a country with a high prevalence of adult HIV.[@R88] The divergences with the South African study can be due to the absence of a booster dose of PCV and to an overall PCV coverage of \< 20%. It is known that herd immunity efficacy is affected by serotype distribution, actual proportion of children vaccinated and also by social factors.

In addition, the effect of possible replacement disease due to non-vaccine serotypes negating any decrease in vaccine-serotype disease also requires evaluation in settings with high HIV burden after PCV introduction.
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